Introduction
Recent evidence suggests that neoplastic development, at least in part, is the result of the abnormal activation of a small set of cellular genes. These genes, termed proto-oncogenes, were originally discovered as the transduced genes of acute transforming retroviruses (1) (2) (3) . Subsequent studies have established that these proto-oncogenes can also be activated as oncogenes by mechanisms independent of retroviruses (4) . Mechanisms for the conversion of proto-oncogenes to activated oncogenes include point mutations, gene amplification, chromosomal rearrangements, and promoter insertion (Fig. 1) . The activation of proto-oncogenes by genetic alterations results in altered levels of expression of the normal protein product, or in normal or altered levels of expression of an abnormal protein.
Proto-oncogenes are expressed during regulated growth such as embryogenesis, regeneration of damaged liver, and stimulation of cell mitosis by growth factors. Proto-oncogenes are highly conserved. They are detected in species as divergent as yeast, Drosophila, and humans. Proto-oncogenes include genes that encode for growth factors (sis), growth factor receptors (neu, erbB, fms), regulatory proteins in signal transduction (ras family), nuclear regulatory proteins (myc, myb, fos), and tyrosine kinases (scr, abl, ras). Thus, the encoded proteins appear to play a crucial role in normal cellular growth and/or differentiation.
The activation of proto-oncogenes in spontaneous and chemically induced tumors has been extensively studied during the past several years. Although oncogenes such as ras and myc can complement each other in the malignant transformation of a cell in vitro (2) , the number of proto-oncogenes that must be activated in the multistep process of carcinogenesis is unclear at present. Also, new evidence from several laboratories suggests that in addition to the activation of positive factors (oncogenes), the loss of negative regulatory functions (tumor suppressor genes) may also be a necessary but distinct step in neoplastic development (5) . This paper will discuss the detection of activated oncogenes in rodent tumors and the implication of oncogenes in risk analysis of carcinogen-induced rodent tumor data.
Detection of Activated Oncogenes in Tumors
Detection of activated oncogenes in neoplasia can be achieved by using several different techniques depending on how the particular oncogene might be activated. (31) gene. The selected cells are then injected SC into the immunocompromised mice. The tumors that develop from the nude mice are then analyzed using the techniques described earlier to characterize the activated oncogenes.
The majority of activated genes in human tumors detected by the NIH/3T3 assay have been members of the ras gene family: the H-ras, the K-ras, and the N-ras. Early studies using the NIH/3T3 assay showed only ras gene activation in a low percentage ofthe human tumors (approximately 10%). Later studies have shown that other oncogenes can also be detected in the human tumors by this assay, including the Ica (8) , hst (9) , and the trk (10) oncogenes. In addition, the percentage of certain tumor types that test positive for activated ras oncogenes are higher than 10%. For example, VerlaandeVries et al. (11) detected activated ras genes in the 27% of acute myeloid leukemia examined. Ananthaswamy et al. (12) detected Ha-ras genes in four of six human squamous cell carcinomas examined. The addition of the tumorigenicity parameter to the assay system appears to improve the efficiency in detection of activated oncogenes in human tumors.
A variety of animal tumor model systems have also been examined for activated genes using the NIH/3T3 assay. These include spontaneous tumors in rats and mice, tumors that arise after single or multiple doses of carcinogen, and tumors that arise after long-tern exposure to a carcinogen. Examples of the activated genes in the different tumor model systems are shown in Table 2 . Like the human tumors, the majority of activated oncogenes detected in the animal tumors are members of the ras gene family. Other oncogenes have also been detected in animal tumors using the NIH/3T3 assay (Table 3) . One 
Activation of Oncogenes by Carcinogens
Studies in animal tumor model systems suggest that the chemicals or radiation may play a role in the activation of oncogenes by point mutation. Point mutations resulting in the activation ofras proto-oncogenes in several chemically induced rodent tumors have been consistent with the known alkylation patterns of the carcinogens (13) . For example, the mutation at the 12th codon of the H-ras gene detected in rat mammary tumors induced by methylnitrosourea (14) is consistent with the formation of the o6 methylguanine adduct. The activating mutation in the 61st codon of the H-ras gene found in 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors and skin tumors is consistent with DMBA binding to adenosine residues (15) . The point mutation that activates the neu proto-oncogene in peripheral nervous system tumors in rats induced by ENU or MNU probably results from the binding of these potent genotoxic chemicals to DNA (16) . "Hot spots" for activating mutations in these oncogenes have been observed (17) . For example, the GGA-* GAA mutation observed in the 12th codon of ras oncogenes detected in MNU-induced mammary carcinomas (14) is always at the second guanine of this codon, even though a similar mutation at the first guanine could also produce an activated ras oncogene. If oncogenes with GC--AT transitions in the second base of the 12th codon are spontaneous, since an activated K-ras with the same mutation was observed in a spontaneously occurring pulmonary adenocarcinoma in the B6C3F1 mouse (U.Candrian, unpublished data). Even though spontaneous lung tumors in the Fischer 344 rat were not observed in this study, it is still possible that the irritant property of TNM could have promoted the cells, which activated the K-ras or enhanced the spontaneously occurring K-ras. The reproducible detection of the K-ras in lung tumors of mice and rats suggests that TNM could have directly induced the mutation. In support of this conclusion, mutagenicity studies have shown that TNM causes mutant bacterial strains to revert to the wild type by the same GC-*AT transition. Studies on the possible interactions of TNM with DNA are required to precisely determine the origin of the activated K-ras oncogenes in these TNM-induced lung tumors.
Although gene amplification and chromosomal translocation have been observed in several types of human tumors, these activating mechanisms have not been extensively observed or studied in spontaneous or chemically induced rodent tumors. Sawey et al. (20) did observe c-myc gene amplification and restriction polymorphisms in addition to activated K-ras genes in rat skin tumors induced by ionizing radiation. Quintanilla et al. (21) suggested that amplification of the mutated H-ras gene may be involved in the progression of mouse skin papillomas to carcinomas. Further studies are required to determine the possible role of chemicals and radiation in the activation of proto-oncogenes by gene amplification, chromosomal translocation, and other mechanisms that can alter gene expression.
Carcinogen-induced rodent tumor models may be useful in determining the temporal activation of oncogenes in tumor development. Evidence in several animal studies suggests that activation of the ras proto-oncogene is an early event. The activated ras gene has been detected in many benign tumors, including mouse skin papillomas, mouse lung and liver adenomas, and basal cell and clitoral gland tumors of the rat. This implies that the activated ras was present in the cell that clonally expanded to these benign tumors. In addition, it was recently shown that mouse epidermal cells injected in vivo with the viral Ha-ras gene can be promoted with 12-0-tetradecanoyl-phorbol-13-acetate (TPA) to papillomas (22) . Thus, activation of the ras proto-oncogene may be the initiation event in some model systems. Moreover, dormant initiated cells with the activated ras gene can survive surrounded by normal cells until stimulated to proliferate by some endogenous or exogenous agent.
Implications for Risk Analysis
The number of proto-oncogenes that must be activated in order to convert a normal cell into one that is tumorigenic is unknown at present. However, there is increasing evidence that the transformation of a normal cell into a tumorigenic cell involves the activation and concerted expression of several proto-oncogenes as well as, perhaps, the inactivation of suppressor genes. Continued research on mechanisms of oncogene activation in animal and in vitro models may provide new insights into several long-standing problems in chemical carcinogenesis and risk analysis of carcinogenesis data.
Oncogene analysis on tumors from long-term carcinogenesis studies that are employed to help identify potential human carcinogens can be useful in several ways. The analysis can help identify chemicals that can activate proto-oncogenes in vivo to cancer-causing genes. Model systems very susceptible to chemically induced tumors, such as the B6C3F1 mouse liver tumors, appear to be suited for this purpose (23) . The classification of chemicals as initiators, promoters, complete carcinogens, etc., may become clearer as we better understand the sequential requirements for activation of oncogenes in the various animal model and cell culture systems. In particular, comparison of patterns of oncogene activation in spontaneously occurring and chemical-induced tumors should assist in determining mode(s) of action of a carcinogen. Low-dose and species-to-species extrapolation ofrisk from carcinogenic data may become more reliable from examination of oncogene activation and expression in animal model systems for carcinogenesis. These and similar approaches to explore the mechanisms by which chemicals induce tumors in animal model systems may remove some of the uncertainty in risk analysis of rodent carcinogenic data.
